Mathias Kroll | Chief Business Officer
Cynata Therapeutics Ltd

Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd

Dr Mathias Kroll has over 25 years’ experience in biopharmaceutical research and business development. He joined the Company in April 2024 as Chief Business Officer. Dr. Kroll has extensive global experience in biopharmaceutical business transactions of all kinds and has created and managed a large number of partnerships ranging in value up to several billion dollars.
His previous appointments are Chief Commercial Officer, QIMR Berghofer (AUS), Chief Executive Officer, InProTher ApS (DK, now Hervolution Therapeutics), Global Head of Business Development, Bavarian Nordic (DK), Sr Director Global Business Development, GlaxoSmithKline Vaccines (BE), Assoc. Product Director and Global Brand Manager, UCB (BE), Assoc. Director Business Development, UCB Japan (JP), Research Unit Head, Sanofi (FR), Laboratory Head, Bayer Healthcare (DE), Vis. Assoc. Consultant, Boston Consulting Group (DE), and Research Associate, INSERM (FR). Following studies and research work performed at the Universities of Dusseldorf (DE), Paris (FR), North Carolina at Chapel Hill (USA), and at IMD in Lausanne (CH), Dr Kroll holds Master’s degrees in Chemistry, Biology, and Business Administration, a diploma in Molecular Virology, and a PhD in Viral Immunology for work performed at Pasteur Institute (FR). He is a member of the Australian Institute of Company Directors and served on the panel of CUREator, Australia’s national biotech incubator.

Appearances:



Day 1: 18th March 2025 @ 13:40

Clinical development of iPSC-derived mesenchymal stem cells

last published: 05/Nov/24 17:25 GMT

back to speakers


Get Involved with Advanced Therapies Congress

 

To sponsor or exhibit

Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032

 

To speak

Chris Shanks
Chris.Shanks@terrapinn.com
+44 207 092 1150